Publication

This report provides practical policy recommendations to help deliver better, safer, and cheaper medicine and treatment to the 1 billion people suffering from neglected diseases. A surge in funding in the past decade is good news: dozens of candidate drugs and vaccines are now in the pipeline. But before these products can reach the people who need them, they must be tested in risky, expensive, and time-consuming clinical trials with highly vulnerable patients in resource- and infrastructure-poor countries. There is simply not enough funding to support the costs and regulatory oversight of such clinical trials.